A detailed history of Commodore Capital LP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Commodore Capital LP holds 825,000 shares of SNDX stock, worth $15.8 Million. This represents 1.52% of its overall portfolio holdings.

Number of Shares
825,000
Previous 318,851 158.74%
Holding current value
$15.8 Million
Previous $7.59 Million 123.21%
% of portfolio
1.52%
Previous 0.66%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$18.82 - $23.79 $9.53 Million - $12 Million
506,149 Added 158.74%
825,000 $16.9 Million
Q1 2024

May 15, 2024

BUY
$19.71 - $24.57 $6.28 Million - $7.83 Million
318,851 New
318,851 $7.59 Million
Q3 2023

Nov 14, 2023

SELL
$14.52 - $21.77 $582,063 - $872,693
-40,087 Reduced 4.02%
957,509 $13.9 Million
Q2 2023

Aug 14, 2023

BUY
$19.35 - $22.31 $2.78 Million - $3.21 Million
143,712 Added 16.83%
997,596 $20.9 Million
Q1 2023

May 15, 2023

BUY
$20.66 - $28.98 $3.42 Million - $4.79 Million
165,439 Added 24.03%
853,884 $18 Million
Q4 2022

Feb 14, 2023

SELL
$20.64 - $26.24 $1.03 Million - $1.3 Million
-49,665 Reduced 6.73%
688,445 $17.5 Million
Q3 2022

Nov 14, 2022

BUY
$18.51 - $24.79 $13.7 Million - $18.3 Million
738,110 New
738,110 $17.7 Million
Q2 2021

Aug 16, 2021

SELL
$13.42 - $25.18 $3.17 Million - $5.96 Million
-236,500 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$19.28 - $24.59 $1.81 Million - $2.31 Million
-93,815 Reduced 28.4%
236,500 $5.29 Million
Q4 2020

Feb 16, 2021

BUY
$15.1 - $26.44 $4.99 Million - $8.73 Million
330,315 New
330,315 $7.35 Million

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $1.08B
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Commodore Capital LP Portfolio

Follow Commodore Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Commodore Capital LP with notifications on news.